Drugs / IBI376
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05073250 | Dec 2021 → Dec 2023 | indolent B-cell non-Hodgkin lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04298879 | Apr 2020 → Jul 2021 | indolent B-cell non-Hodgkin lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-03-31 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces Parsaclisib (IBI376) was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Follicular Lymphoma innoventbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI376 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04298879 ↗ |
| Known as | INCB050465 | “IBI376 (INCB050465) is a second generation, effective and highly selective PI3Kδ inhibitor.” NCT05073250 ↗ |
| Action | Inhibit | “IBI376, a PI3Kδ Inhibitor” NCT04298879 ↗ |
| Route | Oral | “IBI376 will be administered orally” NCT04298879 ↗ |